Annie Vu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Annie Vu has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Scarlett Lin Gomez
Department of Epidemiology and Biostatistics University of California San Francisco San Francisco California USA
6 shared publications - Iona Cheng
Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, USA
5 shared publications - Katherine Lin
Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California
5 shared publications - Salma Shariff-Marco
Department of Epidemiology and Biostatistics, University of California , San Francisco, CA
5 shared publications - Alice Guan
Department of Epidemiology and Biostatistics, School of Medicine, University of California San Francisco, San Francisco, California
4 shared publications - Alison J. Canchola
Department of Epidemiology and Biostatistics, University of California, San Francisco (UCSF), San Francisco, California
4 shared publications
Latest Publications
- 3 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- p. OF1-OF12
Hispanic and Asian American/Pacific Islander Ethnic Enclave, Neighborhood Socioeconomic Status, and Renal Cell Carcinoma Incidence in California
Background: We evaluated associations of neighborhood socioeconomic status (nSES) and ethnic enclave with renal cell carcinoma (RCC) incidence among Hispanic and Asian American/Pacific Islander (AAPI) populations in California. Methods: We conducted a population-based study of 7,507 Hispanic and 2,293 AAPI individuals diagnosed with RCC in the California Cancer Registry across three Census periods (1988–1992, 1998–2002, and 2008–2012). Race- and ethnicity-specific Census population counts were used to estimate incidence rate ratios (IRR) and 95% confidence intervals (CI) across nSES and ethnic enclave quintiles (Q) and a joint variable of dichotomous nSES (high vs. low) and ethnic enclave (enclave vs. nonenclave). Results: Higher nSES was associated with higher RCC incidence among AAPI individuals (Q5 vs. Q1: IRR, 1.50; 95% CI, 1.27–1.78) and modestly elevated incidence among Hispanic individuals in intermediate quintiles. Less ethnically distinct neighborhoods were associated with higher incidence among Hispanic individuals (Q1 vs. Q5: IRR, 1.21; 95% CI, 1.10–1.34), whereas no clear pattern was observed among AAPI individuals. Compared with low-nSES/enclave neighborhoods, RCC incidence was higher in all other joint nSES/enclave categories in both populations. These associations were generally similar by sex, age at diagnosis, and tumor histology and were mainly observed for localized-stage RCC. Conclusions: Hispanic and AAPI individuals living in higher-nSES neighborhoods had higher RCC incidence, whereas Hispanic individuals living in less ethnically distinct neighborhoods had higher RCC incidence. These patterns may reflect differences in healthcare access, diagnostic intensity, and neighborhood-related etiologic factors. Impact: Neighborhood factors should be considered in RCC etiology, surveillance, and risk stratification research among diverse populations.
- 3 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- p. OF1-OF12
Hispanic and Asian American/Pacific Islander Ethnic Enclave, Neighborhood Socioeconomic Status, and Renal Cell Carcinoma Incidence in California
Background: We evaluated associations of neighborhood socioeconomic status (nSES) and ethnic enclave with renal cell carcinoma (RCC) incidence among Hispanic and Asian American/Pacific Islander (AAPI) populations in California. Methods: We conducted a population-based study of 7,507 Hispanic and 2,293 AAPI individuals diagnosed with RCC in the California Cancer Registry across three Census periods (1988–1992, 1998–2002, and 2008–2012). Race- and ethnicity-specific Census population counts were used to estimate incidence rate ratios (IRR) and 95% confidence intervals (CI) across nSES and ethnic enclave quintiles (Q) and a joint variable of dichotomous nSES (high vs. low) and ethnic enclave (enclave vs. nonenclave). Results: Higher nSES was associated with higher RCC incidence among AAPI individuals (Q5 vs. Q1: IRR, 1.50; 95% CI, 1.27–1.78) and modestly elevated incidence among Hispanic individuals in intermediate quintiles. Less ethnically distinct neighborhoods were associated with higher incidence among Hispanic individuals (Q1 vs. Q5: IRR, 1.21; 95% CI, 1.10–1.34), whereas no clear pattern was observed among AAPI individuals. Compared with low-nSES/enclave neighborhoods, RCC incidence was higher in all other joint nSES/enclave categories in both populations. These associations were generally similar by sex, age at diagnosis, and tumor histology and were mainly observed for localized-stage RCC. Conclusions: Hispanic and AAPI individuals living in higher-nSES neighborhoods had higher RCC incidence, whereas Hispanic individuals living in less ethnically distinct neighborhoods had higher RCC incidence. These patterns may reflect differences in healthcare access, diagnostic intensity, and neighborhood-related etiologic factors. Impact: Neighborhood factors should be considered in RCC etiology, surveillance, and risk stratification research among diverse populations.
- 22 May 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2501134
Evaluating Disparities in Pediatric Cancer Genomic Testing and Sequencing Results at the University of California, San Francisco Using the National Childhood Cancer Registry
PURPOSE: The increasing role of genomic testing in pediatric cancer care decisions may contribute to outcome disparities. We evaluated drivers of genomic testing in the National Childhood Cancer Registry (NCCR) at the University of California, San Francisco (UCSF). MATERIALS AND METHODS: Multilevel data linkages for 1,555 patients with cancer age ≤20 years diagnosed between 2012 and 2019 at the UCSF NCCR were leveraged for a subset of patients who were alive and diagnosed after 2015 following the availability of UCSF500 genomic testing, a panel-based, next-generation cancer tumor and normal sequencing assay. Risk ratios (RR) and 95% CI of testing were estimated using Poisson regression. The prevalence of pathogenic variants and variants of uncertain significance (VUS) was generated for tested patients. RESULTS: Of the 758 eligible patients, 262 (34.6%) were tested. In fully adjusted models, adoption of genomic testing increased over time (2019 v 2016: RR, 2.06 [95% CI, 1.49 to 2.86]), whereas older age (ages 15-19 v <5 years: RR, 0.69 [95% CI, 0.52 to 0.91]), female versus male sex (RR, 0.81 [95% CI, 0.66 to 0.98]), and living in a rural versus urban/suburban area (RR, 0.60 [95% CI, 0.38 to 0.96]) were independently associated with lower genomic testing. Compared with solid tumors, lymphomas were less likely (RR, 0.49 [95% CI, 0.24 to 0.98]) and CNS tumors were more likely (RR, 1.70 [95% CI, 1.37 to 2.12]) to be tested. Among the tested patients, the prevalence of pathogenic variants and VUS did not differ by race/ethnicity or neighborhood socioeconomic status. CONCLUSION: Our work highlights the need for more equitable genomic testing practices in pediatric cancer care to reduce clinical outcome disparities and demonstrates how the population-based integrated database generated for the UCSF NCCR serves as a valuable resource for advancing epidemiologic research for patients with pediatric cancer.
- 22 May 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2501134
Evaluating Disparities in Pediatric Cancer Genomic Testing and Sequencing Results at the University of California, San Francisco Using the National Childhood Cancer Registry
PURPOSE: The increasing role of genomic testing in pediatric cancer care decisions may contribute to outcome disparities. We evaluated drivers of genomic testing in the National Childhood Cancer Registry (NCCR) at the University of California, San Francisco (UCSF). MATERIALS AND METHODS: Multilevel data linkages for 1,555 patients with cancer age ≤20 years diagnosed between 2012 and 2019 at the UCSF NCCR were leveraged for a subset of patients who were alive and diagnosed after 2015 following the availability of UCSF500 genomic testing, a panel-based, next-generation cancer tumor and normal sequencing assay. Risk ratios (RR) and 95% CI of testing were estimated using Poisson regression. The prevalence of pathogenic variants and variants of uncertain significance (VUS) was generated for tested patients. RESULTS: Of the 758 eligible patients, 262 (34.6%) were tested. In fully adjusted models, adoption of genomic testing increased over time (2019 v 2016: RR, 2.06 [95% CI, 1.49 to 2.86]), whereas older age (ages 15-19 v <5 years: RR, 0.69 [95% CI, 0.52 to 0.91]), female versus male sex (RR, 0.81 [95% CI, 0.66 to 0.98]), and living in a rural versus urban/suburban area (RR, 0.60 [95% CI, 0.38 to 0.96]) were independently associated with lower genomic testing. Compared with solid tumors, lymphomas were less likely (RR, 0.49 [95% CI, 0.24 to 0.98]) and CNS tumors were more likely (RR, 1.70 [95% CI, 1.37 to 2.12]) to be tested. Among the tested patients, the prevalence of pathogenic variants and VUS did not differ by race/ethnicity or neighborhood socioeconomic status. CONCLUSION: Our work highlights the need for more equitable genomic testing practices in pediatric cancer care to reduce clinical outcome disparities and demonstrates how the population-based integrated database generated for the UCSF NCCR serves as a valuable resource for advancing epidemiologic research for patients with pediatric cancer.
- 24 April 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (8) , 1646-1654
Historical redlining and mortality in children, adolescents, and young adults with cancer in California, 2000-2019
Background: Historical redlining, or the Home Owners’ Loan Corporation (HOLC) program’s racially biased mortgage risk monitoring maps in the 1930s, is implicated in shaping modern neighborhoods and health outcomes. This retrospective cohort study evaluates the association between redlining and mortality in young cancer patients. Methods: Using the California Cancer Registry, we identified patients aged younger than 25 years diagnosed with malignant cancer between 2000 and 2019. HOLC maps were spatially joined with patient address at diagnosis to determine redlining status (A [best], B [still desirable], C [declining], D [hazardous]). Census tract-level US Census and American Community Survey data were appended to determine modern neighborhood characteristics. The Kaplan–Meier method was used to evaluate overall survival and multivariable Cox proportional hazards models to estimate the associations between HOLC grade and mortality, adjusting for clinical and multilevel social drivers of health. Results: In total, 8108 patients resided in HOLC-graded neighborhoods among 51 084 patients statewide. Overall survival at 5 years was inferior for patients who resided in D-graded neighborhoods at diagnosis vs A-graded neighborhoods (80.3%, 95% confidence interval [CI] = 78.6% to 81.8%, vs 88.5%, 95% CI = 84.3% to 91.6%). Adjusting for clinical characteristics, patients in D-graded neighborhoods experienced greater mortality (hazard ratio [HR] = 1.32, 95% CI = 1.12 to 1.56) compared with those in A- and B-graded neighborhoods. Additional adjustment for insurance attenuated the effect (HR = 1.17, 95% CI = 1.00 to 1.36), and for neighborhood, socioeconomic status marginally attenuated the effect (HR = 0.96, 95% CI = 0.81 to 1.13). Conclusion: Findings suggest enduring legacy effects of historical redlining on young individuals with cancer potentially mediated social factors, including health insurance.
- 24 April 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (8) , 1646-1654
Historical redlining and mortality in children, adolescents, and young adults with cancer in California, 2000-2019
Background: Historical redlining, or the Home Owners’ Loan Corporation (HOLC) program’s racially biased mortgage risk monitoring maps in the 1930s, is implicated in shaping modern neighborhoods and health outcomes. This retrospective cohort study evaluates the association between redlining and mortality in young cancer patients. Methods: Using the California Cancer Registry, we identified patients aged younger than 25 years diagnosed with malignant cancer between 2000 and 2019. HOLC maps were spatially joined with patient address at diagnosis to determine redlining status (A [best], B [still desirable], C [declining], D [hazardous]). Census tract-level US Census and American Community Survey data were appended to determine modern neighborhood characteristics. The Kaplan–Meier method was used to evaluate overall survival and multivariable Cox proportional hazards models to estimate the associations between HOLC grade and mortality, adjusting for clinical and multilevel social drivers of health. Results: In total, 8108 patients resided in HOLC-graded neighborhoods among 51 084 patients statewide. Overall survival at 5 years was inferior for patients who resided in D-graded neighborhoods at diagnosis vs A-graded neighborhoods (80.3%, 95% confidence interval [CI] = 78.6% to 81.8%, vs 88.5%, 95% CI = 84.3% to 91.6%). Adjusting for clinical characteristics, patients in D-graded neighborhoods experienced greater mortality (hazard ratio [HR] = 1.32, 95% CI = 1.12 to 1.56) compared with those in A- and B-graded neighborhoods. Additional adjustment for insurance attenuated the effect (HR = 1.17, 95% CI = 1.00 to 1.36), and for neighborhood, socioeconomic status marginally attenuated the effect (HR = 0.96, 95% CI = 0.81 to 1.13). Conclusion: Findings suggest enduring legacy effects of historical redlining on young individuals with cancer potentially mediated social factors, including health insurance.
- Open Access
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Disparities in Cancer Stage Shifts Associated with the COVID-19 Pandemic in California, 2020 to 2021
Supplemental Table 1. Population counts per pandemic time period and absolute change in percentage of late-stage cancer diagnoses for Post-Shutdown #2 and Post-Vaccine Rollout
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Disparities in Cancer Stage Shifts Associated with the COVID-19 Pandemic in California, 2020 to 2021
Supplemental Table 1. Population counts per pandemic time period and absolute change in percentage of late-stage cancer diagnoses for Post-Shutdown #2 and Post-Vaccine Rollout
- Open Access
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Data from Disparities in Cancer Stage Shifts Associated with the COVID-19 Pandemic in California, 2020 to 2021
Background:The COVID-19 pandemic and associated shutdowns disrupted healthcare access and resulted in decreased cancer screenings. Cancer diagnosis delays have concerning downstream effects on late-stage cancer, especially for marginalized populations.Methods:The study population included 349,458 adults in the California Cancer Registry diagnosed with cancer between January 2019 and December 2021, during which California experienced two stay-at-home orders. We examined the percentage of late-stage (III–IV) cancer diagnoses across five periods: Pre-pandemic (January 2019–February 2020), Shutdown #1 (March–June 2020), Post-shutdown #1 (July–November 2020), Post-shutdown #2 (December 2020–March 2021), and Post-vaccine rollout (April–December 2021). To examine the association between time period and late-stage diagnoses, we conducted a multivariable log-binomial regression model adjusted for sociodemographic and neighborhood factors.Results:The percentage of late-stage cancer diagnoses increased during Shutdown #1 (+5.2%) and returned to baseline Post-vaccine rollout. Groups with notably higher increases in the percentage of late-stage cancer (vs. overall population) during Shutdown #1 include Pacific Islander (+13.7%), Thai (+11.2%), Chinese (+8.1%), Native Hawaiian (+7.4%), Filipino (+6.6%), and uninsured (+7.4%). Uninsured [vs. private insurance; prevalence ratio (PR), 1.41], low neighborhood socioeconomic status (nSES; vs. high; PR, 1.19), and racial and ethnic minoritized groups (vs. non-Hispanic White; PR, 1.04–1.19) had higher likelihood for late-stage cancer diagnosis.Conclusions:The pandemic exacerbated late-stage cancer disparities for racial and ethnic minoritized groups, underinsured, and low nSES communities in California (2020–2021).Impact:Interventions to improve cancer screening must be focused on racial and ethnic minoritized, underinsured, and low nSES communities, as they are likely to be more vulnerable to healthcare disruptions like the pandemic.
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Disparities in Cancer Stage Shifts Associated with the COVID-19 Pandemic in California, 2020 to 2021
Background:The COVID-19 pandemic and associated shutdowns disrupted healthcare access and resulted in decreased cancer screenings. Cancer diagnosis delays have concerning downstream effects on late-stage cancer, especially for marginalized populations.Methods:The study population included 349,458 adults in the California Cancer Registry diagnosed with cancer between January 2019 and December 2021, during which California experienced two stay-at-home orders. We examined the percentage of late-stage (III–IV) cancer diagnoses across five periods: Pre-pandemic (January 2019–February 2020), Shutdown #1 (March–June 2020), Post-shutdown #1 (July–November 2020), Post-shutdown #2 (December 2020–March 2021), and Post-vaccine rollout (April–December 2021). To examine the association between time period and late-stage diagnoses, we conducted a multivariable log-binomial regression model adjusted for sociodemographic and neighborhood factors.Results:The percentage of late-stage cancer diagnoses increased during Shutdown #1 (+5.2%) and returned to baseline Post-vaccine rollout. Groups with notably higher increases in the percentage of late-stage cancer (vs. overall population) during Shutdown #1 include Pacific Islander (+13.7%), Thai (+11.2%), Chinese (+8.1%), Native Hawaiian (+7.4%), Filipino (+6.6%), and uninsured (+7.4%). Uninsured [vs. private insurance; prevalence ratio (PR), 1.41], low neighborhood socioeconomic status (nSES; vs. high; PR, 1.19), and racial and ethnic minoritized groups (vs. non-Hispanic White; PR, 1.04–1.19) had higher likelihood for late-stage cancer diagnosis.Conclusions:The pandemic exacerbated late-stage cancer disparities for racial and ethnic minoritized groups, underinsured, and low nSES communities in California (2020–2021).Impact:Interventions to improve cancer screening must be focused on racial and ethnic minoritized, underinsured, and low nSES communities, as they are likely to be more vulnerable to healthcare disruptions like the pandemic.
- Open Access
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Disparities in Cancer Stage Shifts Associated with the COVID-19 Pandemic in California, 2020 to 2021
Supplemental Figure 1. Age distributions from 2019 vs. 2021 from American Community Survey (ACS) 2019-2021
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Disparities in Cancer Stage Shifts Associated with the COVID-19 Pandemic in California, 2020 to 2021
Supplemental Figure 1. Age distributions from 2019 vs. 2021 from American Community Survey (ACS) 2019-2021
- 31 October 2024
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (1) , 139-150
Disparities in Cancer Stage Shifts Associated with the COVID-19 Pandemic in California, 2020 to 2021
Background: The COVID-19 pandemic and associated shutdowns disrupted healthcare access and resulted in decreased cancer screenings. Cancer diagnosis delays have concerning downstream effects on late-stage cancer, especially for marginalized populations. Methods: The study population included 349,458 adults in the California Cancer Registry diagnosed with cancer between January 2019 and December 2021, during which California experienced two stay-at-home orders. We examined the percentage of late-stage (III–IV) cancer diagnoses across five periods: Pre-pandemic (January 2019–February 2020), Shutdown #1 (March–June 2020), Post-shutdown #1 (July–November 2020), Post-shutdown #2 (December 2020–March 2021), and Post-vaccine rollout (April–December 2021). To examine the association between time period and late-stage diagnoses, we conducted a multivariable log-binomial regression model adjusted for sociodemographic and neighborhood factors. Results: The percentage of late-stage cancer diagnoses increased during Shutdown #1 (+5.2%) and returned to baseline Post-vaccine rollout. Groups with notably higher increases in the percentage of late-stage cancer (vs. overall population) during Shutdown #1 include Pacific Islander (+13.7%), Thai (+11.2%), Chinese (+8.1%), Native Hawaiian (+7.4%), Filipino (+6.6%), and uninsured (+7.4%). Uninsured [vs. private insurance; prevalence ratio (PR), 1.41], low neighborhood socioeconomic status (nSES; vs. high; PR, 1.19), and racial and ethnic minoritized groups (vs. non-Hispanic White; PR, 1.04–1.19) had higher likelihood for late-stage cancer diagnosis. Conclusions: The pandemic exacerbated late-stage cancer disparities for racial and ethnic minoritized groups, underinsured, and low nSES communities in California (2020–2021). Impact: Interventions to improve cancer screening must be focused on racial and ethnic minoritized, underinsured, and low nSES communities, as they are likely to be more vulnerable to healthcare disruptions like the pandemic.
- 31 October 2024
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (1) , 139-150
Disparities in Cancer Stage Shifts Associated with the COVID-19 Pandemic in California, 2020 to 2021
Background: The COVID-19 pandemic and associated shutdowns disrupted healthcare access and resulted in decreased cancer screenings. Cancer diagnosis delays have concerning downstream effects on late-stage cancer, especially for marginalized populations. Methods: The study population included 349,458 adults in the California Cancer Registry diagnosed with cancer between January 2019 and December 2021, during which California experienced two stay-at-home orders. We examined the percentage of late-stage (III–IV) cancer diagnoses across five periods: Pre-pandemic (January 2019–February 2020), Shutdown #1 (March–June 2020), Post-shutdown #1 (July–November 2020), Post-shutdown #2 (December 2020–March 2021), and Post-vaccine rollout (April–December 2021). To examine the association between time period and late-stage diagnoses, we conducted a multivariable log-binomial regression model adjusted for sociodemographic and neighborhood factors. Results: The percentage of late-stage cancer diagnoses increased during Shutdown #1 (+5.2%) and returned to baseline Post-vaccine rollout. Groups with notably higher increases in the percentage of late-stage cancer (vs. overall population) during Shutdown #1 include Pacific Islander (+13.7%), Thai (+11.2%), Chinese (+8.1%), Native Hawaiian (+7.4%), Filipino (+6.6%), and uninsured (+7.4%). Uninsured [vs. private insurance; prevalence ratio (PR), 1.41], low neighborhood socioeconomic status (nSES; vs. high; PR, 1.19), and racial and ethnic minoritized groups (vs. non-Hispanic White; PR, 1.04–1.19) had higher likelihood for late-stage cancer diagnosis. Conclusions: The pandemic exacerbated late-stage cancer disparities for racial and ethnic minoritized groups, underinsured, and low nSES communities in California (2020–2021). Impact: Interventions to improve cancer screening must be focused on racial and ethnic minoritized, underinsured, and low nSES communities, as they are likely to be more vulnerable to healthcare disruptions like the pandemic.